>
Fa   |   Ar   |   En
   low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis  
   
نویسنده takaishi koji ,tsukamoto shokichi ,ohwada chikako ,takeuchi masahiro ,kawasaki yohei ,nagai yurie ,mishina tatsuzo ,yamazaki miki ,isshiki yusuke ,kayamori kensuke ,kimura kenji ,hino yutaro ,oshima-hasegawa nagisa ,mitsukawa shio ,takeda yusuke ,mimura naoya ,iseki tohru ,nakaseko chiaki ,sakaida emiko
منبع journal of thrombosis and thrombolysis - 2019 - دوره : 48 - شماره : 1 - صفحه:141 -148
چکیده    Anti-platelet agents or anticoagulants are administered for patients with multiple myeloma (mm) receiving immunomodulatory drugs (imids) to prevent thrombotic events (tes). however, there is a discrepancy between current guidelines and clinical practice in thromboprophylaxis and the varied incidence of tes depending on patient cohort. therefore, a consensus on the optimal thromboprophylactic strategy is needed. to determine an appropriate strategy for the prevention of tes in mm patients receiving imids, we performed a retrospective single-institution analysis. in total, 95 mm patients (62% male, median age 65 years, range 30–85 years) from 2008 to 2018 were recruited, and 140 cases were analyzed in the medical-record-based study. thromboprophylactic drugs were given to 69% of patients, anti-platelet agents to 66%, and anticoagulants to 3.0%. seven tes (5.0%) and six bleeding events (4.3%) were observed, but no patients died from thrombohemorrhage. the median follow-up period was 184 days (range 21–2224), and the cumulative te incidence was 1.7% at 3 months, 7.0% at 1 year, and 12.5% at 3 years. multivariate analysis determined that age > 70 years (p = 0.012) and bmi < 18.5 kg/m2 (p = 0.042) were the significant risk factors of te. a low incidence of tes was observed despite the low adherence to guideline recommendations for anticoagulant administration. these results suggest that anti-platelet agents are sufficient for thromboprophylaxis. a high-risk group of tes in mm patients receiving imids was identified, and a larger study is needed to confirm these findings.
کلیدواژه multiple myeloma ,thromboembolism ,anticoagulants ,hemorrhage ,risk assessment
آدرس chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, japan, chiba university hospital, clinical research center, biostatistics section, japan, chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, department of transfusion medicine and cell therapy, japan, chiba university hospital, department of hematology, japan, chiba university hospital, department of hematology, department of transfusion medicine and cell therapy, japan, chiba university hospital, department of hematology, department of transfusion medicine and cell therapy, japan, chiba university hospital, department of hematology, japan. international university of health and welfare school of medicine, department of hematology, japan, chiba university hospital, department of hematology, japan
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved